Hyperthyroidism — the active hypersecretion of thyroid hormones by the thyroid gland — affects approximately 1-2% of the population, with a higher prevalence in women. The direct consequence is the acceleration of metabolism throughout the body, with cardiovascular, neuropsychiatric, muscular, and reproductive manifestations. Although it can be bothersome and, in severe forms, associated with serious complications, hyperthyroidism responds well to treatment when correctly diagnosed and managed.
Hyperthyroidism affects approximately 1-2% of the population, with a higher prevalence in women. Although it can be bothersome and, in severe forms, dangerous, the good news is that effective and well-tolerated therapeutic options exist. However, the choice of appropriate treatment depends on the cause of the disease, symptom severity, age, and the patient’s individual context.
In this article, we explain what hyperthyroidism is, why it occurs, how it manifests, and, most importantly, what treatment options are available, along with their advantages and limitations.
What is hyperthyroidism and how does it occur?
Hyperthyroidism is a condition in which the thyroid gland produces an excessive amount of thyroid hormones (T3 and T4), leading to an acceleration of metabolism throughout the body. TSH is usually low or undetectable, as the pituitary gland attempts to inhibit thyroid stimulation.
It is important to differentiate hyperthyroidism from thyrotoxicosis: thyrotoxicosis is the clinical state of excess thyroid hormones in the blood, regardless of the cause (including exogenous sources or passive release from an inflamed gland). Hyperthyroidism itself implies active hypersecretion by the thyroid.
Causes of hyperthyroidism
| Cause | Mechanism and characteristics |
| Graves’ disease (60-80% of cases) | TRAb antibodies stimulate TSH receptors: the most common cause; diffuse goiter, possible ophthalmopathy |
| Toxic multinodular goiter | Autonomous hyperfunctioning nodules; common in elderly individuals with long-standing goiter |
| Toxic adenoma (solitary hyperfunctioning nodule) | A single nodule produces hormones autonomously, independent of TSH |
| Thyroiditis (subacute, postpartum, Hashimoto’s) | Passive release of hormones from an inflamed thyroid: transient thyrotoxicosis |
| Excessive iodine intake (Jod-Basedow phenomenon) | Sudden iodine intake (radiological contrast, amiodarone) in individuals with nodular goiter |
| Iatrogenic hyperthyroidism | Levothyroxine overdose in the treatment of hypothyroidism |
Symptoms of hyperthyroidism
Symptoms are the expression of general metabolic acceleration and excessive adrenergic stimulation:
| Affected system | Common symptoms |
| Cardiovascular | Palpitations, tachycardia (rapid heart rate), atrial fibrillation (in severe forms), systolic hypertension |
| Metabolic / Weight | Weight loss with increased appetite, heat intolerance, excessive sweating |
| Neuromuscular | Fine hand tremor, proximal muscle weakness, fatigue |
| Psychological | Anxiety, irritability, emotional lability, difficulty concentrating, insomnia |
| Gastrointestinal | Accelerated bowel transit, diarrhea, nausea |
| Integumentary / Hair | Warm and moist skin, hair loss, brittle nails |
| Reproductive | Irregular or reduced menstrual cycle, decreased fertility, gynecomastia in men |
| Ocular (Graves’ disease) | Exophthalmos (protrusion of eyeballs), double vision, ocular irritation, eyelid retraction |
Palpitations, tremor, unexplained weight loss, or persistent anxiety can be signs of hyperthyroidism. A complete endocrinological evaluation at Arthope clarifies the diagnosis and establishes the treatment plan. Schedule an endocrinology consultation.
Treatment options for hyperthyroidism
There are three main categories of hyperthyroidism treatment. None is universally superior; the choice depends on the cause, severity, age, reproductive context, and patient preferences.
1. Antithyroid drugs (ATDs)
These are the first line of treatment in many cases, especially in Graves’ disease and in young patients. They inhibit the synthesis of thyroid hormones in the thyroid gland.
- Methimazole (Thiamazole): the drug of choice for most patients; loading dose followed by maintenance dose; administered once or twice daily
- Propylthiouracil (PTU): preferred in the first trimester of pregnancy and in thyrotoxic crisis; also inhibits peripheral T4-T3 conversion
Duration of treatment in Graves’ disease: 12-18 months, aiming for remission. Remission rate after a first cycle: 30-50%. Relapse after stopping treatment: frequent (40-60%).
Adverse effects to monitor: agranulocytosis (rare but severe: sudden fever requires immediate discontinuation and urgent tests), hepatotoxicity, allergic skin reactions.
2. Radioactive iodine (I-131 radioiodine therapy)
Oral administration of radioactive iodine is selectively absorbed by the thyroid and progressively destroys hypertrophied tissue. It is a definitive, effective, and safe option for most adult patients.
- Main indications: recurrent Graves’ disease after ATDs, toxic multinodular goiter, toxic adenoma, elderly patients with comorbidities
- Advantage: definitive treatment, no surgery, simple administration (one capsule or oral solution)
- Main disadvantage: post-treatment hypothyroidism (in 50-90% of patients) — requires lifelong levothyroxine
- Contraindicated in pregnancy and breastfeeding; pregnancy should be avoided 6-12 months after treatment
- Graves’ disease with severe active ophthalmopathy: radioiodine therapy can worsen ophthalmopathy; used with caution
3. Surgical intervention (thyroidectomy)
Partial or total thyroidectomy is a definitive option with rapid and predictable results.
- Indications: large goiter with compressive symptoms, suspicion of malignancy, severe Graves’ ophthalmopathy, contraindications to other options, patient preference
- Advantage: rapid effect, complete control of thyroid function, possibility of histological examination
- Disadvantage: surgical risks (transient or permanent hypoparathyroidism, recurrent laryngeal nerve injury; rare in specialized centers)
- After total thyroidectomy: lifelong levothyroxine
Symptomatic treatment with beta-blockers
Beta-blockers (propranolol, atenolol, metoprolol) do not treat the cause of hyperthyroidism but rapidly control cardiovascular and neurovegetative symptoms — tachycardia, palpitations, tremor, anxiety. They are used in conjunction with one of the definitive treatments.
Comparison of treatment options
| Criterion | ATD Medications | Radioactive Iodine | Surgery |
| Definitive effect | No (frequent relapses) | Yes | Yes |
| Post-treatment hypothyroidism | No (if remission) | Frequent (50-90%) | Frequent after total thyroidectomy |
| Indicated in pregnancy | Yes (PTU in trimester I, methimazole in trimesters II-III) | No | Possible in trimester II |
| Time to control | Weeks | Months | Weeks |
| Surgical risk | No | No | Minimal in specialized centers |
| Long-term monitoring | Required | Required (TSH) | Required (TSH) |
| Remission rate | 30-50% after 12-18 months (frequent relapses) | Hypothyroidism in 50-90% (definitive treatment) | Hypothyroidism after total thyroidectomy (definitive treatment) |
Hyperthyroidism in pregnancy: a special case
Uncontrolled hyperthyroidism in pregnancy is associated with significant risks: miscarriage, premature birth, low birth weight, thyrotoxic crisis. Management requires balancing the risks of treatment with the risks of untreated disease:
- Propylthiouracil (PTU) is preferable in the first trimester (methimazole is associated with rare malformations)
- Methimazole can be used from the second trimester if PTU is not tolerated
- Doses should be reduced to the minimum effective level; the goal is FT4 in the upper normal range (approximately 1.0-1.5x the upper limit of the laboratory’s reference interval), avoiding overdose which can affect the fetus
- Radioactive iodine is absolutely contraindicated in pregnancy
- Surgery can be performed, if necessary, in the second trimester
At Arthope, the management of hyperthyroidism in pregnancy is carried out in collaboration between the endocrinologist and the obstetrician, with monitoring every 4-6 weeks.
Not all forms of hyperthyroidism require the same treatment. At Arthope, you benefit from a complete evaluation and personalized therapeutic recommendation — medication, radioactive iodine, or surgery — depending on the cause, age, and individual context. Request an endocrinology consultation at Arthope.
Checklist: When to consult an endocrinologist for hyperthyroidism
- You have frequent palpitations or an accelerated heart rate without exertion
- You are losing weight without changing your diet or physical activity
- You have hand tremor, especially fine tremor at rest
- You feel anxious, irritable, or unable to relax
- You sweat excessively and cannot tolerate heat
- You have an irregular menstrual cycle or difficulty conceiving
- You have noticed ocular changes: eye protrusion, double vision, irritation
- Your TSH is low or undetectable in tests
- You are undergoing treatment with amiodarone or iodinated contrast and are experiencing new symptoms
How Arthope approaches hyperthyroidism
At Arthope, the diagnosis and treatment of hyperthyroidism are approached with an integral perspective:
- Complete biochemical evaluation: TSH, FT4, FT3, TRAb (specific antibodies for Graves’ disease), anti-TPO antibodies
- Thyroid ultrasound with Doppler in the office — for evaluating gland vascularization and structure
- Thyroid scintigraphy (if necessary) for differentiating the cause
- Selection of personalized therapeutic option — based on cause, age, planned pregnancy, comorbidities
- Structured monitoring: follow-up every 4-6 weeks after treatment initiation, dose adjustment, remission evaluation
- Reproductive perspective: for women desiring pregnancy, the treatment protocol includes optimizing thyroid function prior to conception
Frequently asked questions about hyperthyroidism treatment
Not necessarily. Antithyroid drug treatment lasts 12-18 months in Graves’ disease, with a 30-50% chance of remission. If remission is achieved and sustained, treatment can be stopped under supervision. Radioiodine therapy and surgery are definitive treatments, but often lead to hypothyroidism requiring lifelong levothyroxine.
Radioiodine therapy with I-131 has a well-documented safety profile, used for over 70 years. It does not increase the risk of thyroid cancer or other types of cancer at standard therapeutic doses. The main long-term consequence is hypothyroidism, which is easily treated with levothyroxine.
Uncontrolled hyperthyroidism reduces fertility and increases the risk of complications in pregnancy. With adequate treatment and normalized thyroid function, pregnancy is possible. It is essential to plan pregnancy with an endocrinologist, who will adapt the treatment to the requirements of the preconception period and pregnancy.
Graves’ disease can go into remission after 12-18 months of drug treatment — in approximately 30-50% of patients. Remission can be permanent or temporary. Factors associated with better remission rates include: small goiter, initially low TRAb, mild hyperthyroidism. Definitive treatments (radioactive iodine, surgery) eliminate hyperfunction but do not treat the autoimmune component.
Untreated hyperthyroidism exposes the patient to significant risks: atrial fibrillation (risk of stroke), accelerated osteoporosis, heart failure, thyrotoxic crisis (a medical emergency with high mortality). Therefore, diagnosis and initiation of treatment should not be delayed.
Conclusion
Hyperthyroidism is a treatable condition with very good outcomes, provided correct diagnosis and selection of the appropriate therapeutic option. There is no universal treatment; the decision is individualized, taking into account the cause, age, desire for pregnancy, and patient preferences.
Do not delay a consultation if you have suggestive symptoms. Early diagnosis and adequate treatment prevent cardiovascular, bone, and reproductive complications.
Schedule an endocrinology consultation at Arthope and benefit from a complete evaluation and a personalized therapeutic plan.






